EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Neurological disease in xeroderma pigmentosum: prospective cohort study of its features and progression

Hector Garcia-Moreno iD, Douglas R Langbehn iD, Adesoji Abiona iD, Isabel Garrood, Zofia Fleszar, Marta Antonia Manes, Ana M Susana Morley, Emma Craythorne, Shehla Mohammed iD, Tanya Henshaw, Sally Turner iD, Harsha Naik und 5 weitere

Brain · 01.12.2023 · 146 (12) · 5044-5059

DOI: 10.1093/brain/awad266 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Brain, online erschienen am 01.12.2023. Verfasst von Hector Garcia-Moreno und 16 weiteren Autor:innen. Beteiligte Einrichtung: Ataxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK. Hauptthemen laut MEDLINE: Xeroderma Pigmentosum, Central Nervous System Diseases. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NHS England, National Institute for Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Xeroderma pigmentosum (XP) results from biallelic mutations in any of eight genes involved in DNA repair systems, thus defining eight different genotypes (XPA, XPB, XPC, XPD, XPE, XPF, XPG and XP variant or XPV). In addition to cutaneous and ophthalmological features, some patients present with XP neurological disease. It is unknown whether the different neurological signs and their progression differ among groups. Therefore, we aim to characterize the XP neurological disease and its evolution in the heterogeneous UK XP cohort. Patients with XP were followed in the UK National XP Service, from 2009 to 2021. Age of onset for different events was recorded. Cerebellar ataxia and additional neurological signs and symptoms were rated with the Scale for the Assessment and Rating of Ataxia (SARA), the Inventory of Non-Ataxia Signs (INAS) and the Activities of Daily Living questionnaire (ADL). Patients’ mutations received scores based on their predicted effects. Data from available ancillary tests were collected. Ninety-three XP patients were recruited. Thirty-six (38.7%) reported neurological symptoms, especially in the XPA, XPD and XPG groups, with early-onset and late-onset forms, and typically appearing after cutaneous and ophthalmological symptoms. XPA, XPD and XPG patients showed higher SARA scores compared to XPC, XPE and XPV. SARA total scores significantly increased over time in XPD (0.91 points/year, 95% confidence interval: 0.61, 1.21) and XPA (0.63 points/year, 95% confidence interval: 0.38, 0.89). Hyporeflexia, hypopallesthaesia, upper motor neuron signs, chorea, dystonia, oculomotor signs and cognitive impairment were frequent findings in XPA, XPD and XPG. Cerebellar and global brain atrophy, axonal sensory and sensorimotor neuropathies, and sensorineural hearing loss were common findings in patients. Some XPC, XPE and XPV cases presented with abnormalities on examination and/or ancillary tests, suggesting underlying neurological involvement. More severe mutations were associated with a faster progression in SARA total score in XPA (0.40 points/year per 1-unit increase in severity score) and XPD (0.60 points/year per 1-unit increase), and in ADL total score in XPA (0.35 points/year per 1-unit increase). Symptomatic and asymptomatic forms of neurological disease are frequent in XP patients, and neurological symptoms can be an important cause of disability. Typically, the neurological disease will be preceded by cutaneous and ophthalmological features, and these should be actively searched in patients with idiopathic late-onset neurological syndromes. Scales assessing cerebellar function, especially walking and speech, and disability can show progression in some of the groups. Mutation severity can be used as a prognostic biomarker for stratification purposes in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Xeroderma PigmentosumCentral Nervous System DiseasesHumansActivities of Daily LivingProspective StudiesDNA RepairMutation

Stichwörter der Autor:innen

DNA repairHuntington’s disease-like phenotypesbiomarkerscerebellar ataxianeurocutaneous syndromesnucleotide excision repair

Autor:innen und Institutionen

  • Ataxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.
  • Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA.
  • UK National Xeroderma Pigmentosum Service, Guy's and St Thomas' NHS Foundation Trust, London SE1 7EH, UK.
  • Department of Ophthalmology, Guy's and St Thomas' NHS Foundation Trust, London SE1 7EH, UK.
  • Clinical Neuropathology, Academic Neuroscience Building, King's College Hospital, London SE5 9RS, UK.
  • Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, Brighton BN1 9RQ, UK.

ORCID-Profile: Hector Garcia-Moreno, Douglas R Langbehn, Adesoji Abiona, Shehla Mohammed, Sally Turner, Istvan Bodi, Hiva Fassihi, Alan R Lehmann, Paola Giunti

Förderung

  • Medical Research Council
  • NHS England
  • National Institute for Health
  • North Thames CRN
  • Department of Health’s

Zitieren

APA

Garcia-Moreno, H., Langbehn, D. R., Abiona, A., Garrood, I., Fleszar, Z., Manes, M. A., Morley, A. M. S., Craythorne, E., Mohammed, S., Henshaw, T., Turner, S., Naik, H., Bodi, I., Sarkany, R. P. E., Fassihi, H., Lehmann, A. R., & Giunti, P. (2023). Neurological disease in xeroderma pigmentosum: prospective cohort study of its features and progression. Brain, 146(12), 5044-5059. https://doi.org/10.1093/brain/awad266

Vancouver

Garcia-Moreno H, Langbehn DR, Abiona A, Garrood I, Fleszar Z, Manes MA, et al. Neurological disease in xeroderma pigmentosum: prospective cohort study of its features and progression. Brain. 2023;146(12):5044-5059. doi:10.1093/brain/awad266

BibTeX
@article{GarciaMoreno2023,
  author = {Garcia-Moreno, Hector and Langbehn, Douglas R and Abiona, Adesoji and Garrood, Isabel and Fleszar, Zofia and Manes, Marta Antonia and Morley, Ana M Susana and Craythorne, Emma and Mohammed, Shehla and Henshaw, Tanya and Turner, Sally and Naik, Harsha and Bodi, Istvan and Sarkany, Robert P E and Fassihi, Hiva and Lehmann, Alan R and Giunti, Paola},
  title = {Neurological disease in xeroderma pigmentosum: prospective cohort study of its features and progression},
  journal = {Brain},
  year = {2023},
  volume = {146},
  number = {12},
  pages = {5044--5059},
  doi = {10.1093/brain/awad266}
}
Kostenlos starten →